January 9, 2007
EPITOMICS ANNOUNCES THE CREATION OF 500th RABBIT MONOCLONAL ANTIBODY

Burlingame, CA, USA - Epitomics, Inc., the rabbit monoclonal antibody technology company, announced today that it has now produced and launched 500 new rabbit monoclonal antibodies. Each created in house utilizing Epitomics' proprietary rabbit monoclonal antibody technology. The number of rabbit monoclonal antibodies in Epitomics' catalog continues to grow at an average pace of seven new novel antibodies per week.

Epitomics has developed a unique and proprietary method for making monoclonal antibodies using rabbits rather the conventional method of starting with mice. The advantages of Epitomics' rabbit monoclonal antibodies include high specificity and affinity, excellent results in a variety of assays including westerns, IHC, ICC, IP and flow cytometry, and the ability to generate monoclonal antibodies to targets not possible using mice.

"We are very pleased to have reached the 500 rabbit monoclonal antibody mark in a relatively short period of time" said Dr. Peter Li, Senior Vice-President of Product Development. "The products we have released are among the most extensively characterized reagent antibodies on the market and we plan to continue our pace of monoclonal antibody development into 2007 and beyond".

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb technology with superior binding affinity and bioactivity in a wide variety of biological assays. The Company is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. More information about Epitomics can be found at www.epitomics.com

About RabMab

RabMab technology is used for the discovery and development of monoclonal antibodies to treat cancer and other diseases. Compared to currently available MAb technology on the market, such as mouse hybridomas, Epitomics' technology can generate RabMAbs more efficiently and can offer RabMAbs with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle.